PavlÃ-na HaÅ¡kovÃ¡

List of Publications by Year
in descending order

27	708	471509 17	526287 27
papers	citations	h-index	g-index

27	27	27	1129
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. Scientific Reports, 2022, 12, .	3.3	2
2	Structureâ€“Activity Relationships of Nitro-Substituted Aroylhydrazone Iron Chelators with Antioxidant and Antiproliferative Activities. Chemical Research in Toxicology, 2018, 31, 435-446.	3.3	5
3	Intravenous rutin in rat exacerbates isoprenaline-induced cardiotoxicity likely due to intracellular oxidative stress. Redox Report, 2017, 22, 78-90.	4.5	6
4	Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity. Archiv Der Pharmazie, 2017, 350, 1700020.	4.1	5
5	Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	4.0	4
6	Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology, 2016, 350-352, 15-24.	4.2	10
7	Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. European Journal of Medicinal Chemistry, 2016, 120, 97-110.	5.5	31
8	Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury. Toxicology, 2016, 371, 17-28.	4.2	14
9	Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicology Research, 2015, 4, 1098-1114.	2.1	20
10	In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS ONE, 2015, 10, e0139929.	2.5	7
11	Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs. PLoS ONE, 2014, 9, e88754.	2.5	23
12	Cucurbitacin E Has Neuroprotective Properties and Autophagic Modulating Activities on Dopaminergic Neurons. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-15.	4.0	35
13	Structure-Activity Relationships of Novel Salicylaldehyde Isonicotinoyl Hydrazone (SIH) Analogs: Iron Chelation, Anti-Oxidant and Cytotoxic Properties. PLoS ONE, 2014, 9, e112059.	2.5	15
14	Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. Free Radical Biology and Medicine, 2014, 74, 210-221.	2.9	28
15	Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells. PLoS ONE, 2013, 8, e76676.	2.5	58
16	Chronic Anthracycline Cardiotoxicity: Molecular and Functional Analysis with Focus on Nuclear Factor Erythroid 2-Related Factor 2 and Mitochondrial Biogenesis Pathways. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 468-478.	2.5	48
17	Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: Novel iron chelators with selective antiproliferative action. Chemico-Biological Interactions, 2012, 197, 69-79.	4.0	41
18	Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity. Toxicology, 2011, 289, 122-131.	4.2	35

#	Article	IF	Citations
19	Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity. Free Radical Biology and Medicine, 2011, 50, 537-549.	2.9	42
20	Synthesis and Initial in Vitro Evaluations of Novel Antioxidant Aroylhydrazone Iron Chelators with Increased Stability against Plasma Hydrolysis. Chemical Research in Toxicology, 2011, 24, 290-302.	3.3	52
21	In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Archives of Toxicology, 2011, 85, 525-535.	4.2	24
22	Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical Research in Toxicology, 2010, 23, 1105-1114.	3.3	61
23	Direct administration of rutin does not protect against catecholamine cardiotoxicity. Toxicology, 2009, 255, 25-32.	4.2	15
24	The Novel Iron Chelator, 2-Pyridylcarboxaldehyde 2-Thiophenecarboxyl Hydrazone, Reduces Catecholamine-Mediated Myocardial Toxicity. Chemical Research in Toxicology, 2009, 22, 208-217.	3.3	27
25	Antiproliferative effects of selenium compounds in colon cancer cells: Comparison of different cytotoxicity assays. Toxicology in Vitro, 2009, 23, 1406-1411.	2.4	35
26	HPLC-DAD and MS/MS analysis of novel drug candidates from the group of aromatic hydrazones revealing the presence of geometric isomers. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 295-302.	2.8	23
27	Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. British Journal of Pharmacology, 2008, 155, 138-148.	5.4	42